Ligand Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020
Net Income	110.94	22.12	20.3	-13.32	-1.2
Depreciation & Amortization	12.63	7.51	5.07	5.2	4.39
Other Operating Activities	17.84	9.3	5.42	6.31	9.47
Change in Accounts Receivable	-13.11	-32.28	2.52	-2.45	-14.33
Change in Inventory	-258.13	-52.44	-6	-	-
Change in Accounts Payable	46.14	22.4	5.33	14.48	15.68
Change in Other Net Operating Assets	-420.69	-19.67	-24.38	-13.82	-5.62
Operating Cash Flow	-504.39	-43.06	8.25	-3.61	8.39
Capital Expenditures	-25.69	-20.76	-10.2	-5.82	-21.09
Investment in Securities	-6.72	-6.5	-	-	-
Other Investing Activities	0.72	0.08	-	-	-
Investing Cash Flow	-31.69	-27.13	-10.2	-5.82	-21.17
Short-Term Debt Issued	-	-	0.08	17.77	16.44
Long-Term Debt Issued	-	19.38	3.67	-	0.27
Total Debt Issued	-	19.38	3.75	17.77	16.71
Short-Term Debt Repaid	-40.41	-23.4	-	-	-
Long-Term Debt Repaid	-18.75	-	-	-3.11	-
Total Debt Repaid	-59.15	-23.4	-	-3.11	-
Net Debt Issued (Repaid)	-59.15	-4.03	3.75	14.66	16.71
Issuance of Common Stock	637.78	83.44	-	4.82	-
Other Financing Activities	32.57	-9.26	-5.38	-5.91	-5.67
Financing Cash Flow	611.2	70.15	-1.63	13.58	11.04
Miscellaneous Cash Flow Adjustments	-	-	-	-0	0
Net Cash Flow	75.12	-0.04	-3.58	4.14	-1.74
Free Cash Flow	-530.07	-63.82	-1.95	-9.44	-12.7
Free Cash Flow Margin	-40.86%	-7.67%	-0.41%	-2.44%	-3.62%
Free Cash Flow Per Share	-61.16	-7.56	-0.32	-1.57	-2.22
Cash Interest Paid	18.58	9.26	5.38	5.91	5.67
Cash Income Tax Paid	49	8.8	4.22	-	0.72
Levered Free Cash Flow	-554.51	-75.41	-12.5	-11.75	-
Unlevered Free Cash Flow	-548.17	-70.1	-9.13	-8.27	-
Change in Working Capital	-645.79	-81.98	-22.55	-1.79	-4.27

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.